Divergent effects of type-I interferons on regulatory T cells

Cytokine and Growth Factor Reviews

Volumn 26, Issue 2, 2015, Pages 133-141

  Piconese, Silvia ^a   Pacella, Ilenia ^a   Timperi, Eleonora ^a   Barnaba, Vincenzo ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Pasteur Institute   (Italy)

Author keywords

Immunomodulation; Regulatory T cells; Type 1 Interferons

Indexed keywords

ALPHA2 INTEGRIN; CD4 ANTIGEN; GAMMA INTERFERON; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; INTERFERON; INTERFERON REGULATORY FACTOR 4; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; CYTOKINE;

ADAPTIVE IMMUNITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL SURVIVAL; CYTOKINE PRODUCTION; HEPATITIS C; HOMEOSTASIS; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSTIMULATION; INNATE IMMUNITY; INTRACELLULAR SIGNALING; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MULTIPLE SCLEROSIS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION REGULATION; HEPATITIS C, CHRONIC; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INFLAMMATION; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASMS; SIGNAL TRANSDUCTION;

HEPATITIS C VIRUS;

CYTOKINES; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; IMMUNE TOLERANCE; IMMUNOMODULATION; INFLAMMATION; INTERFERON TYPE I; INTERFERONS; LYMPHOCYTE ACTIVATION; MULTIPLE SCLEROSIS; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY;

EID: 84926474925     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.10.012     Document Type: Article

References (68)

1. Theofilopoulos A.N., Baccala R., Beutler B., Kono D.H. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005, 23:307-336.
2. Ivashkiv L.B., Donlin L.T. Regulation of type I interferon responses. Nat Rev Immunol 2014, 14:36-49.
3. Gonzalez-Navajas J.M., Lee J., David M., Raz E. Immunomodulatory functions of type I interferons. Nat Rev Immunol 2012, 12:125-135.
4. Trinchieri G. Type I interferon: friend or foe?. J Exp Med 2010, 207:2053-2063.
5. Burzyn D., Benoist C., Mathis D., Regulatory T cells in nonlymphoid tissues. Nat Immunol 2013, 14:1007-1013.
6. Carbone F., De Rosa V., Carrieri P.B., Montella S., Bruzzese D., Porcellini A., et al. Regulatory T cell proliferative potential is impaired in human autoimmune disease. Nat Med 2014, 20:69-74.
7. Vukmanovic-Stejic M., Zhang Y., Cook J.E., Fletcher J.M., McQuaid A., Masters J.E., et al. Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J Clin Invest 2006, 116:2423-2433.
8. Hippen K.L., Harker-Murray P., Porter S.B., Merkel S.C., Londer A., Taylor D.K., et al. Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. Blood 2008, 112:2847-2857.
9. Piconese S., Timperi E., Pacella I., Schinzari V., Tripodo C., Rossi M., et al. Human OX40 tunes the function of regulatory T cells in tumor and nontumor areas of hepatitis C virus-infected liver tissue. Hepatology 2014, 60:1494-1507.
10. Pace L., Vitale S., Dettori B., Palombi C., La Sorsa V., Belardelli F., et al. APC activation by IFN-alpha decreases regulatory T cell and enhances Th cell functions. J Immunol 2010, 184:5969-5979.
11. Katakura K., Lee J., Rachmilewitz D., Li G., Eckmann L., Raz E. Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J Clin Invest 2005, 115:695-702.
12. Lee S.E., Li X., Kim J.C., Lee J., Gonzalez-Navajas J.M., Hong S.H., et al. Type I interferons maintain Foxp3 expression and T-regulatory cell functions under inflammatory conditions in mice. Gastroenterology 2012, 143:145-154.
13. Kole A., He J., Rivollier A., Silveira D.D., Kitamura K., Maloy K.J., et al. Type I IFNs regulate effector and regulatory T cell accumulation and anti-inflammatory cytokine production during T cell-mediated colitis. J Immunol 2013, 191:2771-2779.
14. Chen M., Chen G., Deng S., Liu X., Hutton G.J., Hong J. IFN-beta induces the proliferation of CD4+ CD25+ Foxp3+ regulatory T cells through upregulation of GITRL on dendritic cells in the treatment of multiple sclerosis. J Neuroimmunol 2012, 242:39-46.
15. Franceschini D., Paroli M., Francavilla V., Videtta M., Morrone S., Labbadia G., et al. PD-L1 negatively regulates CD4+ CD25+ Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Invest 2009, 119:551-564.
16. Burocchi A., Colombo M.P., Piconese S. Convergences and divergences of thymus- and peripherally derived regulatory T cells in cancer. Front Immunol 2013, 4:247.
17. Burocchi A., Pittoni P., Gorzanelli A., Colombo M.P., Piconese S. Intratumor OX40 stimulation inhibits IRF1 expression and IL-10 production by Treg cells while enhancing CD40L expression by effector memory T cells. Eur J Immunol 2011, 41:3615-3626.
18. Stewart C.A., Metheny H., Iida N., Smith L., Hanson M., Steinhagen F., et al. Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation. J Clin Invest 2013, 123:4859-4874.
19. Bacher N., Raker V., Hofmann C., Graulich E., Schwenk M., Baumgrass R., et al. Interferon-alpha suppresses cAMP to disarm human regulatory T cells. Cancer Res 2013, 73:5647-5656.
20. Yan B., Ye S., Chen G., Kuang M., Shen N., Chen S. Dysfunctional CD4+, CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells. Arthritis Rheum 2008, 58:801-812.
21. Golding A., Rosen A., Petri M., Akhter E., Andrade F. Interferon-alpha regulates the dynamic balance between human activated regulatory and effector T cells: implications for antiviral and autoimmune responses. Immunology 2010, 131:107-117.
22. Mao C., Wang S., Xiao Y., Xu J., Jiang Q., Jin M., et al. Impairment of regulatory capacity of CD4+ CD25+ regulatory T cells mediated by dendritic cell polarization and hyperthyroidism in Graves' disease. J Immunol 2011, 186:4734-4743.
23. Sisirak V., Faget J., Gobert M., Goutagny N., Vey N., Treilleux I., et al. Impaired IFN-alpha production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res 2012, 72:5188-5197.
24. Srivastava S., Koch M.A., Pepper M., Campbell D.J. Type I interferons directly inhibit regulatory T cells to allow optimal antiviral T cell responses during acute LCMV infection. J Exp Med 2014, 211:961-974.
25. Srivastava S., Koch L.K., Campbell D.J. IFNalphaR signaling in effector but not regulatory T cells is required for immune dysregulation during Type I IFN-dependent inflammatory disease. J Immunol 2014, 193:2733-2742.
26. Barnaba V., Schinzari V. Induction, control, and plasticity of Treg cells: the immune regulatory network revised. Eur J Immunol 2013, 43:318-322.
27. Le Buanec H., Gougeon M.L., Mathian A., Lebon P., Dupont J.M., Peltre G., et al. IFN-alpha and CD46 stimulation are associated with active lupus and skew natural T regulatory cell differentiation to type 1 regulatory T (Tr1) cells. Proc Natl Acad Sci U S A 2011, 108:18995-19000.
28. Roncarolo M.G., Gregori S., Bacchetta R., Battaglia M. Tr1 cells and the counter-regulation of immunity: natural mechanisms and therapeutic applications. Curr Top Microbiol Immunol 2014, 380:39-68.
29. Groux H., O'Garra A., Bigler M., Rouleau M., Antonenko S., de Vries J.E., et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997, 389:737-742.
30. Levings M.K., Sangregorio R., Galbiati F., Squadrone S., de Waal Malefyt R., Roncarolo M.G. IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. J Immunol 2001, 166:5530-5539.
31. Ziegler-Heitbrock L., Lotzerich M., Schaefer A., Werner T., Frankenberger M., Benkhart E. IFN-alpha induces the human IL-10 gene by recruiting both IFN regulatory factor 1 and Stat3. J Immunol 2003, 171:285-290.
32. Dikopoulos N., Bertoletti A., Kroger A., Hauser H., Schirmbeck R., Reimann J. Type I IFN negatively regulates CD8+ T cell responses through IL-10-producing CD4+ T regulatory 1 cells. J Immunol 2005, 174:99-109.
33. Liu Y., Carlsson R., Comabella M., Wang J., Kosicki M., Carrion B., et al. FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS. Nat Med 2014, 20:272-282.
34. Zhou X., Bailey-Bucktrout S., Jeker L.T., Bluestone J.A. Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol 2009, 21:281-285.
35. Hori S. Lineage stability and phenotypic plasticity of Foxp3(+) regulatory T cells. Immunol Rev 2014, 259:159-172.
36. Koch M.A., Thomas K.R., Perdue N.R., Smigiel K.S., Srivastava S., Campbell D.J. T-bet(+) Treg cells undergo abortive Th1 cell differentiation due to impaired expression of IL-12 receptor beta2. Immunity 2012, 37:501-510.
37. Koenecke C., Lee C.W., Thamm K., Fohse L., Schafferus M., Mittrucker H.W., et al. IFN-gamma production by allogeneic Foxp3+ regulatory T cells is essential for preventing experimental graft-versus-host disease. J Immunol 2012, 189:2890-2896.
38. Zhao J., Fett C., Trandem K., Fleming E., Perlman S. IFN-gamma- and IL-10-expressing virus epitope-specific Foxp3(+) T reg cells in the central nervous system during encephalomyelitis. J Exp Med 2011, 208:1571-1577.
39. Oldenhove G., Bouladoux N., Wohlfert E.A., Hall J.A., Chou D., Dos Santos L., et al. Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection. Immunity 2009, 31:772-786.
40. Dominguez-Villar M., Baecher-Allan C.M., Hafler D.A. Identification of T helper type 1-like, Foxp3+ regulatory T cells in human autoimmune disease. Nat Med 2011, 17:673-675.
41. Du W., Shen Y.W., Lee W.H., Wang D., Paz S., Kandeel F., et al. Foxp3+ Treg expanded from patients with established diabetes reduce Helios expression while retaining normal function compared to healthy individuals. PLOS ONE 2013, 8:e56209.
42. McClymont S.A., Putnam A.L., Lee M.R., Esensten J.H., Liu W., Hulme M.A., et al. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol 2011, 186:3918-3926.
43. Byrnes A.A., Ma X., Cuomo P., Park K., Wahl L., Wolf S.F., et al. Type I interferons and IL-12: convergence and cross-regulation among mediators of cellular immunity. Eur J Immunol 2001, 31:2026-2034.
44. Nguyen K.B., Cousens L.P., Doughty L.A., Pien G.C., Durbin J.E., Biron C.A. Interferon alpha/beta-mediated inhibition and promotion of interferon gamma: STAT1 resolves a paradox. Nat Immunol 2000, 1:70-76.
45. Zheng Y., Chaudhry A., Kas A., deRoos P., Kim J.M., Chu T.T., et al. Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. Nature 2009, 458:351-356.
46. Lohoff M., Mak T.W. Roles of interferon-regulatory factors in T-helper-cell differentiation. Nat Rev Immunol 2005, 5:125-135.
47. Wang Z., Zheng Y., Hou C., Yang L., Li X., Lin J., et al. DNA methylation impairs TLR9 induced Foxp3 expression by attenuating IRF-7 binding activity in fulminant type 1 diabetes. J Autoimmun 2013, 41:50-59.
48. Ning S., Pagano J.S., Barber G.N. IRF7: activation, regulation, modification and function. Genes Immun 2011, 12:399-414.
49. Fragale A., Gabriele L., Stellacci E., Borghi P., Perrotti E., Ilari R., et al. IFN regulatory factor-1 negatively regulates CD4+ CD25+ regulatory T cell differentiation by repressing Foxp3 expression. J Immunol 2008, 181:1673-1682.
50. de Andres C., Aristimuno C., de Las Heras V., Martinez-Gines M.L., Bartolome M., Arroyo R., et al. Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis. J Neuroimmunol 2007, 182:204-211.
51. Vandenbark A.A., Huan J., Agotsch M., La Tocha D., Goelz S., Offner H., et al. Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+ CD25+ Foxp3 expression in subjects with multiple sclerosis. J Neuroimmunol 2009, 215:125-128.
52. Namdar A., Nikbin B., Ghabaee M., Bayati A., Izad M. Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study. J Neuroimmunol 2010, 218:120-124.
53. Akiyama M., Ichikawa T., Miyaaki H., Motoyoshi Y., Takeshita S., Ozawa E., et al. Relationship between regulatory T cells and the combination of pegylated interferon and ribavirin for the treatment of chronic hepatitis type C. Intervirology 2010, 53:154-160.
54. Soldevila B., Alonso N., Martinez-Arconada M.J., Morillas R.M., Planas R., Sanmarti A.M., et al. A prospective study of T- and B-lymphocyte subpopulations, CD81 expression levels on B cells and regulatory CD4(+) CD25(+) CD127(low/-) FoxP3(+) T cells in patients with chronic HCV infection during pegylated interferon-alpha2a plus ribavirin treatment. J Viral Hepat 2011, 18:384-392.
55. Kanto T., Inoue M., Oze T., Miyazaki M., Sakakibara M., Kakita N., et al. Dynamics of regulatory T cells and plasmacytoid dendritic cells as immune markers for virological response in pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C patients. J Gastroenterol 2012, 47:169-178.
56. Burton J.R., Klarquist J., Im K., Smyk-Pearson S., Golden-Mason L., Castelblanco N., et al. Prospective analysis of effector and regulatory CD4+ T cells in chronic HCV patients undergoing combination antiviral therapy. J Hepatol 2008, 49:329-338.
57. Wang J-PP, Zhang Y., Wei X., Li J., Nan X.P., Yu H.T., et al. Circulating Toll-like receptor (TLR) 2 TLR4, and regulatory T cells in patients with chronic hepatitis C. APMIS: Acta Pathol Microbiol Immunol Scand 2010, 118:261-270.
58. Hao C., Zhou Y., He Y., Fan C., Sun L., Wei X., et al. Imbalance of regulatory T cells and Th17 cells in patients with chronic hepatitis C. Immunology 2014, (accepted article epub). 10.1111/imm.12330.
59. Wang W., Edington H.D., Rao U.N., Jukic D.M., Radfar A., Wang H., et al. Effects of high-dose IFNalpha2b on regional lymph node metastases of human melanoma: modulation of STAT5, FOXP3, and IL-17. Clin Cancer Res 2008, 14:8314-8320.
60. Riley C.H., Jensen M.K., Brimnes M.K., Hasselbalch H.C., Bjerrum O.W., Straten P.T., et al. Increase in circulating CD4(+)CD25(+)Foxp3(+) T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-alpha. Blood 2011, 118:2170-2173.
61. Ascierto P.A., Napolitano M., Celentano E., Simeone E., Gentilcore G., Daponte A., et al. Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. J Transl Med 2010, 8:76.
62. Spaapen R.M., Leung M.Y., Fuertes M.B., Kline J.P., Zhang L., Zheng Y., et al. Therapeutic activity of high-dose intratumoral IFN-beta requires direct effect on the tumor vasculature. J Immunol 2014, 193:4254-4260.
63. Teijaro J.R., Ng C., Lee A.M., Sullivan B.M., Sheehan K.C., Welch M., et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 2013, 340:207-211.
64. Wilson E.B., Yamada D.H., Elsaesser H., Herskovitz J., Deng J., Cheng G., et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 2013, 340:202-207.
65. Chen L., Borozan I., Feld J., Sun J., Tannis L.L., Coltescu C., et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005, 128:1437-1444.
66. Ji X., Cheung R., Cooper S., Li Q., Greenberg H.B., He X.S. Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. Hepatology 2003, 37:610-621.
67. Sarasin-Filipowicz M., Oakeley E.J., Duong F.H., Christen V., Terracciano L., Filipowicz W., et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008, 105:7034-7039.
68. Sandler N.G., Bosinger S.E., Estes J.D., Zhu R.T., Tharp G.K., Boritz E., et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 2014, 511:601-605.